Biomarker Proteomics
Biomarker proteomics involves the application of proteomic technologies to screen, identify, and validate disease-related biomarkers, facilitating disease diagnosis, prognosis assessment, and therapeutic monitoring. Biomarkers are molecular indicators of specific biological processes under physiological or pathological conditions, widely utilized in oncology, cardiovascular diseases, neurodegenerative disorders, and autoimmune diseases. As primary mediators of cellular functions, proteins exhibit significant alterations during disease onset and progression, making protein biomarkers highly relevant to precision medicine. By leveraging high-throughput mass spectrometry, immunological assays, and bioinformatics tools, biomarker proteomics enables a comprehensive analysis of disease-associated protein expression patterns. This approach aims to identify highly specific and sensitive biomarkers, providing a foundation for early disease detection and personalized treatment. For instance, in cancer research, biomarker proteomics facilitates the identification of protein biomarkers in blood or tissue samples to distinguish cancer patients from healthy individuals, thereby improving early diagnostic accuracy. Prostate-specific antigen (PSA) is a well-established biomarker for prostate cancer, while alpha-fetoprotein (AFP) is commonly used in liver cancer screening. Moreover, biomarker proteomics plays a crucial role in monitoring therapeutic responses, such as assessing HER2 protein levels to guide targeted therapy in breast cancer.
The experimental workflow of biomarker proteomics typically comprises protein sample preparation, high-throughput analysis, data processing, and biomarker validation. Initially, proteins are extracted from biological fluids (e.g., serum, urine, cerebrospinal fluid) or tissue samples, with high-abundance proteins removed to enhance the detection sensitivity of low-abundance biomarkers. Advanced mass spectrometry techniques (e.g., LC-MS/MS) are then employed, utilizing data-dependent acquisition (DDA), data-independent acquisition (DIA), or parallel reaction monitoring (PRM) strategies for accurate protein quantification. Bioinformatics analysis further aids in functional annotation, pathway enrichment, and machine learning-based biomarker selection, followed by validation using ELISA, Western blot, or multiple reaction monitoring (MRM) mass spectrometry to ensure clinical applicability.
Despite notable progress, biomarker proteomics faces challenges such as the vast concentration range of proteins in body fluids, inter-individual biological variability, and the complexity of data interpretation. Integrating multi-omics data, including genomics and metabolomics, with machine learning models holds promise for improving biomarker discovery and disease prediction accuracy.
MtoZ Biolabs provides high-resolution mass spectrometry-based proteomics services, offering optimized sample processing, quantitative analysis, and functional validation to support biomarker research.
MtoZ Biolabs, an integrated chromatography and mass spectrometry (MS) services provider.
Related Services
How to order?
